{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:13:22Z","timestamp":1778170402735,"version":"3.51.4"},"reference-count":96,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82374103"],"award-info":[{"award-number":["82374103"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82330123"],"award-info":[{"award-number":["82330123"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174036"],"award-info":[{"award-number":["82174036"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2632024TD03"],"award-info":[{"award-number":["2632024TD03"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.tips.2026.01.010","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T13:18:00Z","timestamp":1774271880000},"page":"555-570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological strategies targeting hepatocyte-mediated crosstalk in liver fibrosis"],"prefix":"10.1016","volume":"47","author":[{"given":"Yue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Guang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Yue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian-Wen","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2026.01.010_bb0005","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.721","article-title":"Liver cirrhosis: molecular mechanisms and therapeutic interventions","volume":"5","author":"Dong","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.tips.2026.01.010_bb0010","article-title":"Dynamic crosstalk between HSCs and liver microenvironment: multicellular interactions in the regulation of liver fibrosis","volume":"13","author":"Wang","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.tips.2026.01.010_bb0015","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.tips.2025.03.008","article-title":"Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD","volume":"46","author":"Palomer","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2026.01.010_bb0020","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jcmgh.2023.05.010","article-title":"In vivo and in vitro models to study liver fibrosis: mechanisms and limitations","volume":"16","author":"Lee","year":"2023","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcmgh.2023.08.013","article-title":"Hepatocyte FoxO1 deficiency protects from liver fibrosis via reducing inflammation and TGF-\u03b21-mediated HSC activation","volume":"17","author":"Pan","year":"2024","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0035","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2026.01.010_bb0040","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/hep.31582","article-title":"Osteopontin takes center stage in chronic liver disease","volume":"73","author":"Song","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.tips.2026.01.010_bb0045","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/HEP.0000000000000801","article-title":"ASK1\/ p38 axis inhibition blocks the release of mitochondrial \u2018danger signals\u2019 from hepatocytes and suppresses progression to cirrhosis and liver cancer","volume":"80","author":"Peng","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.tips.2026.01.010_bb0050","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","article-title":"Hepatic inflammatory responses in liver fibrosis","volume":"20","author":"Hammerich","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","article-title":"Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues","volume":"65","author":"Parola","year":"2019","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.tips.2026.01.010_bb0060","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2026.01.010_bb0065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0070","doi-asserted-by":"crossref","first-page":"6304","DOI":"10.3748\/wjg.v26.i41.6304","article-title":"Efficacy and safety of anti-hepatic fibrosis drugs","volume":"26","author":"Damiris","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.tips.2026.01.010_bb0075","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2026.01.010_bb0080","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cgh.2023.04.012","article-title":"Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study","volume":"22","author":"Abdelmalek","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0085","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults","volume":"11","author":"Huang","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.tips.2026.01.010_bb0090","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ame2.12437","article-title":"Targeting ASK1 by CS17919 alleviates kidney- and liver-related diseases in murine models","volume":"8","author":"Liao","year":"2025","journal-title":"Anim. Model Exp. Med."},{"key":"10.1016\/j.tips.2026.01.010_bb0095","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jhep.2021.08.011","article-title":"Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model","volume":"75","author":"Yang","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155835","article-title":"Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges","volume":"154","author":"Kokkorakis","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.tips.2026.01.010_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1484278","article-title":"Osteopontin neutralization increases vitamin D receptors on NKT cells and ameliorates liver fibrosis by promoting their activity","volume":"15","author":"Amer","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2026.01.010_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101581","article-title":"MicroRNAs in non-alcoholic fatty liver disease: progress and perspectives","volume":"65","author":"Hochreuter","year":"2022","journal-title":"Mol. Metab."},{"key":"10.1016\/j.tips.2026.01.010_bb0115","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.cell.2024.02.023","article-title":"First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure","volume":"187","author":"Zwirner","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.tips.2026.01.010_bb0120","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.tips.2026.01.010_bb0125","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2026.01.010_bb0130","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0135","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2019.09.050","article-title":"Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis","volume":"18","author":"Bowlus","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0140","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0145","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2026.01.010_bb0150","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0155","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2026.01.010_bb0160","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2026.01.010_bb0165","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cgh.2021.12.044","article-title":"Fenofibrate mitigates hypertriglyceridemia in nonalcoholic steatohepatitis patients treated with cilofexor\/firsocostat","volume":"21","author":"Lawitz","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0170","doi-asserted-by":"crossref","first-page":"7164","DOI":"10.1016\/j.cell.2024.10.001","article-title":"Structure-guided discovery of bile acid derivatives for treating liver diseases without causing itch","volume":"187","author":"Yang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.tips.2026.01.010_bb0175","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115510","article-title":"Design, synthesis and anti-NASH effect evaluation of novel GFT505 derivatives in vitro and in vivo","volume":"257","author":"Xiang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2026.01.010_bb0185","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.tips.2026.01.010_bb0190","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41575-023-00832-w","article-title":"Cellular stress in the pathogenesis of nonalcoholic steatohepatitis and liver fibrosis","volume":"20","author":"Sharma","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0195","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1053\/j.gastro.2016.02.066","article-title":"Pathogenesis of nonalcoholic steatohepatitis","volume":"150","author":"Machado","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2026.01.010_bb0200","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","article-title":"An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH","volume":"79","author":"Tacke","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0205","article-title":"Lipid metabolism in MASLD and MASH: from mechanism to the clinic","volume":"6","author":"Carli","year":"2024","journal-title":"JHEP Rep."},{"key":"10.1016\/j.tips.2026.01.010_bb0210","article-title":"Metabolomics at the cutting edge of risk prediction of MASLD","volume":"5","author":"Tan","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.tips.2026.01.010_bb0215","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3390\/biomedicines12030559","article-title":"Cell death in liver disease and liver surgery","volume":"12","author":"Stoess","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.tips.2026.01.010_bb0220","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1055\/s-0030-1267540","article-title":"Apoptosis as a mechanism for liver disease progression","volume":"30","author":"Guicciardi","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.tips.2026.01.010_bb0225","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41420-023-01749-8","article-title":"Programmed cell death in hepatic fibrosis: current and perspectives","volume":"9","author":"Lu","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.tips.2026.01.010_bb0230","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1111\/bph.15952","article-title":"The pathogenesis of organ fibrosis: focus on necroptosis","volume":"180","author":"Hao","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2026.01.010_bb0235","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jhep.2020.07.041","article-title":"Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis","volume":"74","author":"Gaul","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0240","article-title":"Dual role of pyroptosis in liver diseases: mechanisms, implications, and therapeutic perspectives","volume":"13","author":"Yang","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.tips.2026.01.010_bb0245","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41418-022-00941-0","article-title":"The multifaceted role of ferroptosis in liver disease","volume":"29","author":"Chen","year":"2022","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.tips.2026.01.010_bb0250","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cmet.2024.05.003","article-title":"Metabolic reprogramming in liver fibrosis","volume":"36","author":"Horn","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.tips.2026.01.010_bb0255","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s10565-025-10111-w","article-title":"Ferroptosis in liver fibrosis and its potential intervention strategy","volume":"41","author":"Zhu","year":"2025","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.tips.2026.01.010_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117214","article-title":"Therapeutic potential of ASK1 activators in cancer treatment: current insights and future directions","volume":"178","author":"Wang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.tips.2026.01.010_bb0265","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/bph.14639","article-title":"The MC4 receptor agonist RO27-3225 inhibits NLRP1-dependent neuronal pyroptosis via the ASK1\/JNK\/p38 MAPK pathway in a mouse model of intracerebral haemorrhage","volume":"176","author":"Chen","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2026.01.010_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.129004","article-title":"Astragalus polysaccharides ameliorate osteoarthritis via inhibiting apoptosis by regulating ROS-mediated ASK1\/p38 MAPK signaling pathway targeting on TXN","volume":"258","author":"Xu","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.tips.2026.01.010_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.156239","article-title":"Ginsenoside compound K alleviates brain aging by inhibiting ferroptosis through modulation of the ASK1-MKK7-JNK signaling pathway","volume":"135","author":"Yan","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.tips.2026.01.010_bb0280","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jhep.2025.01.008","article-title":"Hepatocellular CMPK2 promotes the development of metabolic dysfunction-associated steatohepatitis","volume":"83","author":"Zhu","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102131","article-title":"Fibroblast growth factor 21 attenuates iron overload-induced liver injury and fibrosis by inhibiting ferroptosis","volume":"46","author":"Wu","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.tips.2026.01.010_bb0290","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jcmgh.2023.12.009","article-title":"Modulation of hepatocyte nuclear factor 4 alpha (HNF4\u03b1): a critical mechanism of disease progression in liver cirrhosis","volume":"17","author":"Apte","year":"2024","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0295","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1097\/CM9.0000000000002092","article-title":"Hepatocyte nuclear factor 4\u03b1 in the pathogenesis of non-alcoholic fatty liver disease","volume":"135","author":"Pan","year":"2022","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.tips.2026.01.010_bb0300","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/hep.32326","article-title":"Progressive loss of hepatocyte nuclear factor 4 alpha activity in chronic liver diseases in humans","volume":"76","author":"Gunewardena","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.tips.2026.01.010_bb0305","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jcmgh.2023.11.009","article-title":"Mechanism and effect of HNF4\u03b1 decrease in a rat model of cirrhosis and liver failure","volume":"17","author":"Melis","year":"2024","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0310","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.tips.2024.08.009","article-title":"Rezdiffra\u2122 (resmetirom): a THR-\u03b2 agonist for non-alcoholic steatohepatitis","volume":"45","author":"Brisnovali","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2026.01.010_bb0315","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jhep.2023.07.004","article-title":"Treating NASH by targeting peroxisome proliferator-activated receptors","volume":"79","author":"Staels","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0320","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.tips.2026.01.010_bb0325","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0330","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/gutjnl-2021-324305","article-title":"Novel therapeutic targets for cholestatic and fatty liver disease","volume":"71","author":"Trauner","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.tips.2026.01.010_bb0335","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3389\/fimmu.2017.01450","article-title":"The injury-related activation of hedgehog signaling pathway modulates the repair-associated inflammation in liver fibrosis","volume":"8","author":"Shen","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2026.01.010_bb0340","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202405678","article-title":"OPN-mediated crosstalk between hepatocyte e4bp4 and hepatic stellate cells promotes mash-associated liver fibrosis","volume":"11","author":"Wang","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.tips.2026.01.010_bb0345","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jhep.2020.07.030","article-title":"Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice","volume":"73","author":"Du","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0350","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.gastro.2015.05.043","article-title":"Fibroblast growth factor signaling controls liver size in mice with humanized livers","volume":"149","author":"Naugler","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2026.01.010_bb0355","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1146\/annurev-pharmtox-032322-093904","article-title":"Fibroblast growth factor-based pharmacotherapies for the treatment of obesity-related metabolic complications","volume":"63","author":"Jin","year":"2023","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.tips.2026.01.010_bb0360","article-title":"Vicious cycle-breaking lipid nanoparticles remodeling multicellular crosstalk to reverse liver fibrosis","volume":"36","author":"Zhang","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.tips.2026.01.010_bb0365","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/apt.70150","article-title":"Extracellular vesicles mirnome profiling reveals mirnas engagement in dysfunctional lipid metabolism, chronic inflammation and liver damage in subjects with metabolic dysfunction-associated steatotic liver disease","volume":"62","author":"Caviglia","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.tips.2026.01.010_bb0370","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jcmgh.2015.07.007","article-title":"Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-\u03b3","volume":"1","author":"Povero","year":"2015","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0375","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.omtn.2021.10.022","article-title":"Hepatocyte-derived exosomal miR-27a activateshepatic stellate cells through the inhibitionof PINK1-mediated mitophagy in MAFLD","volume":"26","author":"Luo","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.tips.2026.01.010_bb0380","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.31050","article-title":"Lipotoxic hepatocyte-derived exosomal microRNA 192-5p activates macrophages through rictor\/akt\/forkhead box transcription factor O1 signaling in nonalcoholic fatty liver disease","volume":"72","author":"Liu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.tips.2026.01.010_bb0385","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10565-021-09684-z","article-title":"Exosomes derived from hepatitis B virus-infected hepatocytes promote liver fibrosis via miR-222\/TFRC axis","volume":"39","author":"Zhang","year":"2023","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.tips.2026.01.010_bb0390","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3350\/cmh.2022.0032","article-title":"Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment","volume":"29","author":"Park","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemosphere.2020.129177","article-title":"microRNA-21, via the HIF-1\u03b1\/VEGF signaling pathway, is involved in arsenite-induced hepatic fibrosis through aberrant cross-talk of hepatocytes and hepatic stellate cells","volume":"266","author":"Sun","year":"2021","journal-title":"Chemosphere"},{"key":"10.1016\/j.tips.2026.01.010_bb0400","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202201453R","article-title":"Liver-specific deletion of microRNA-34a alleviates ductular reaction and liver fibrosis during experimental cholestasis","volume":"37","author":"Wan","year":"2023","journal-title":"FASEB J."},{"key":"10.1016\/j.tips.2026.01.010_bb0405","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.cmet.2022.05.008","article-title":"MiR-690 treatment causes decreased fibrosis and steatosis and restores specific Kupffer cell functions in NASH","volume":"34","author":"Gao","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.tips.2026.01.010_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102593","article-title":"Hepatocyte delivery of miR-34b\/c reduces hepatic stellate cell activation and improves liver fibrosis","volume":"36","author":"Piccolo","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.tips.2026.01.010_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123321","article-title":"Engineered extracellular vesicles with surface FGF21 and enclosed miR-223 for treating metabolic dysfunction-associated steatohepatitis","volume":"321","author":"Cho","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.tips.2026.01.010_bb0420","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gutjnl-2024-334023","article-title":"Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists","volume":"74","author":"Targher","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.tips.2026.01.010_bb0425","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1038\/s41591-025-03799-0","article-title":"Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Jara","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2026.01.010_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108811","article-title":"Insights into the results of resmetirom trials: can a thyroid hormone receptor agonist be the holy grail of MASH therapy?","volume":"268","author":"Arvanitakis","year":"2025","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tips.2026.01.010_bb0435","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.tips.2026.01.010_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.tips.2026.01.010_bb0445","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jhep.2023.10.042","article-title":"Pharmacologic inhibition of lipogenesis for the treatment of NAFLD","volume":"80","author":"Esler","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tips.2026.01.010_bb0450","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41586-025-08778-6","article-title":"Macrophages harness hepatocyte glutamate to boost liver regeneration","volume":"641","author":"Rigual","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.tips.2026.01.010_bb0455","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.cell.2013.03.026","article-title":"A direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration","volume":"153","author":"Wuestefeld","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.tips.2026.01.010_bb0460","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cmet.2005.08.001","article-title":"Fluid retention mediated by renal PPARgamma","volume":"2","author":"Staels","year":"2005","journal-title":"Cell Metab."},{"key":"10.1016\/j.tips.2026.01.010_bb0465","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2026.01.010_bb0470","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40265-024-02075-8","article-title":"Elafibranor: first approval","volume":"84","author":"Blair","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.tips.2026.01.010_bb0475","article-title":"Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial","volume":"5","author":"Brown","year":"2023","journal-title":"JHEP Rep."},{"key":"10.1016\/j.tips.2026.01.010_bb0480","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.cmet.2024.01.011","article-title":"DGAT2 inhibition blocks SREBP-1 cleavage and improves hepatic steatosis by increasing phosphatidylethanolamine in the ER","volume":"36","author":"Rong","year":"2024","journal-title":"Cell Metab."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726000143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726000143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:25:36Z","timestamp":1778167536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614726000143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0165614726000143"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2026.01.010","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological strategies targeting hepatocyte-mediated crosstalk in liver fibrosis","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2026.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}